Boehringer Ingelheim, Kyowa Kirin enter into license agreement to develop fibro-inflammatory diseases treatment
Ingelheim: Boehringer Ingelheim and Kyowa Kirin Co., Ltd. have announced that they have entered into a license agreement to develop a novel, first-in-class treatment for fibro-inflammatory diseases.
Under the terms of the agreement, Boehringer Ingelheim will receive exclusive, worldwide rights from Kyowa Kirin to develop novel, first-in-class treatments for fibro-inflammatory diseases. Kyowa Kirin is eligible to receive up to EUR 410 million comprising of an upfront payment, success-based development, regulatory, and commercial milestone payments, in addition to royalties on sales.
Fibro-inflammatory diseases result from chronic inflammation caused by a variety of factors including persistent infections, autoimmune reactions, allergic responses and tissue injury. Examples are systemic sclerosis, inflammatory bowel disease, lung fibrosis and others. They are a leading cause of morbidity and mortality. Living with fibro-inflammatory diseases greatly impact patients’ lives, both physically and emotionally and they account for more than one third of deaths worldwide.
“There is a huge remaining unmet patient need in fibro-inflammatory diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “We are very excited about partnering with Kyowa Kirin and being able to add this opportunity to our portfolio to develop new breakthrough treatments for patients with this new collaboration.”
“We are pleased to announce that we have signed the License Agreement with Boehringer Ingelheim.” said Takeyoshi Yamashita, Ph.D., Director of the Board, Chief Medical Officer, Senior Managing Executive Officer of Kyowa Kirin. “The compound was discovered through Kyowa Kirin’s expertise in innovative technology and disease biology. Boehringer Ingelheim is highly regarded for its expertise in fibro-inflammatory diseases, and we believe that they should be the best partner to maximize and deliver the value of our compound for patients in need.”
Read also: Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
